A detailed history of Dowling & Yahnke LLC transactions in Veracyte, Inc. stock. As of the latest transaction made, Dowling & Yahnke LLC holds 60,000 shares of VCYT stock, worth $2.63 Million. This represents 0.46% of its overall portfolio holdings.

Number of Shares
60,000
Holding current value
$2.63 Million
% of portfolio
0.46%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 02, 2022

BUY
$16.58 - $27.9 $994,799 - $1.67 Million
60,000 New
60,000 $996,000
Q4 2021

Feb 10, 2022

SELL
$36.09 - $53.79 $158,796 - $236,676
-4,400 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$35.62 - $52.97 $156,728 - $233,068
-4,400 Reduced 50.0%
4,400 $204,000
Q2 2021

Jul 21, 2021

SELL
$32.94 - $56.62 $145,825 - $250,656
-4,427 Reduced 33.47%
8,800 $352,000
Q4 2020

Jan 28, 2021

BUY
$32.49 - $61.88 $429,745 - $818,486
13,227 New
13,227 $647,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.14B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Dowling & Yahnke LLC Portfolio

Follow Dowling & Yahnke LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dowling & Yahnke LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dowling & Yahnke LLC with notifications on news.